Simulations Plus, Inc ., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the release of NAFLDsym v2B Beta, a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for nonalcoholic steatohepatitis (NASH). This release focused solely on updates to the software infrastructure of NAFLDsym to enable a more intuitive interface design, faster simulations, and more user flexibility.
Mr. Matthew McDaniel , lead programmer on the project, said, “We redesigned the simulation software to use the Julia language, which is geared towards efficient numerical computing. As a result, simulation speed is greatly increased, particularly for large virtual populations. We think the combination of this efficient simulation backend with the updated user interface will make for an excellent user experience.”
CSO Dr. Scott Q. Siler of the DILIsym Services division of Simulations Plus said, “The increase in simulation speed in NAFLDsym v2B Beta enhances predictive capabilities and efficiencies. Moreover, the speed boost allows our QSP modeling team to continue to provide powerful insights related to both NASH pathophysiology and potential treatments for it.”
Key features of NAFLDsym v2B Beta include:
- Integration with a modern C++ based graphical user interface (GUI)
- Integration with the open-source Julia Scientific and Machine Learning (SciML) toolkit to solve simulations efficiently
- Results viewer that can open previously exported results files
- Pre-compiled Julia dependencies so users do not need to install a separate Julia environment
- An interactive console application for editing and appending to existing NAFLDsym QSP model equations
